U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000084: Kansas City Cardiomyopathy Questionnaire (KCCQ)
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000084: Kansas City Cardiomyopathy Questionnaire (KCCQ)

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Cardiology, Hematology, Endocrinology, and Nephrology (OCHEN) 
Division of Cardiovascular and Nephrology (DCN)

DDT COA Number
DDT COA #000084

Instrument Name
Kansas City Cardiomyopathy Questionnaire (KCCQ)

Disease/Condition
Heart Failure (HF)

Concept of Interest
HF symptoms and their impact on physical limitations

Context of Use
Patients with HF

COA Type
PRO

Qualification Stage
Qualified

Requestor(s)
John Spertus

Contact(s)
John Spertus

Date Accepted into CDER’s COA Qualification Program
December 21, 2015

Qualification Date
April 9, 2020
Qualification Statement*

*Under review prior to the passage of the 21st Century Cures Act

Back to Clinical Outcome Assessments (COA) Qualification Submission

Back to Top